Results 21 to 30 of about 28,830 (241)

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

PLoS ONE, 2014
ObjectiveTo assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.MethodsHIV-infected adults with CD4+ T cell count ≤ 200/mm(3) received ...
Laurence Borand, Yoann Madec, Didier Laureillard, Monidarin Chou, Olivier Marcy, Phearavin Pheng, Narom Prak, Chindamony Kim, Khemarin Kim Lak, Chanroeun Hak, Bunnet Dim, Eric Nerrienet, Arnaud Fontanet, Thim Sok, Anne E Goldfeld, François-Xavier Blanc, Anne-Marie Taburet   +16 more
doaj   +1 more source

Late-onset efavirenz toxicity: A descriptive study from Pretoria, South Africa

Southern African Journal of HIV Medicine, 2023
Background: The neuropsychiatric side effects of efavirenz occur mainly early during treatment and are usually mild. A lesser-known and serious complication is late-onset efavirenz toxicity causing ataxia and encephalopathy. Data regarding this condition
Lyneshree Munsami, Clara M. Schutte, Maryke de Villiers, Juliane Hiesgen   +3 more
doaj   +1 more source

Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. [PDF]

, 2012
To investigate the timing, incidence, clinical presentation, pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-infection.
Ngaimisi, E., Klaus-Dieter Riedel, Janabi Mohamed, Bakari, Muhammad, Burhenne Juergen, Minzi, Omary, Eric Sandstrom, Mugusi Sabina, Sandstrom Eric, Mohamed Janabi, Omary Minzi, Mugusi Ferdinand, Bakari Muhammad, Burhenne, J., Eleni Aklillu, Muhammad Bakari, Lars Lindquist, Eliford Ngaimisi, Minzi Omary, Riedel Klaus-Dieter, Mugusi, Sabina, Riedel, Klaus-Dieter, Mugusi, F., Sandstrom, E., Juergen Burhenne, Aklillu, E., Riedel, K.D., Ngaimisi Eliford, Lindquist, Lars, Ferdinand Mugusi, Mugusi, Ferdinand, Burhenne, Juergen, Lindquist, L., Lindquist Lars, Mugusi, S., Janabi, Mohamed, Aklillu, Eleni, Aklillu Eleni, Sandstrom, Eric, Sabina Mugusi, Janabi, M., Minzi, O., Bakari, M., Ngaimisi, Eliford   +43 more
core   +1 more source

AtriplaR/anti-TB Combination in TB/HIV Patients. Drug in Focus. [PDF]

, 2011
Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral
Semvua Hadija H, Kibiki, Gibson S, Hadija H Semvua, Gibson S Kibiki, Semvua, Hadija H, Kibiki Gibson S   +5 more
core   +1 more source

Efavirenz exposure, alone and in combination with known drugs of abuse, engenders addictive-like bio-behavioural changes in rats

Scientific Reports, 2018
Efavirenz is abused in a cannabis-containing mixture known as Nyaope. The addictive-like effects of efavirenz (5, 10 and 20 mg/kg) was explored using conditioned place preference (CPP) in rats following sub-acute exposure vs. methamphetamine (MA; 1 mg/kg)
Marisa Möller, Jaco Fourie, Brian H. Harvey   +2 more
doaj   +1 more source

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania

BMC Pharmacology and Toxicology, 2018
Background Children are subject to varying drug pharmacokinetics which influence plasma drug levels, and hence treatment outcomes especially for drugs like efavirenz whose plasma concentrations are directly related to treatment outcomes.
Selemani Saidi Sungi, Eliford Ngaimisi, Nzovu Ulenga, Philip Sasi, Sabina Mugusi   +4 more
doaj   +1 more source

Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy

, 2022
We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their
Huang, Sung-Hsi;Lin, Shu-Wen;Chang, Sui-Yuan;Lin, Ya-Ting;Chiang, Chieh;Hsiao, Chin-Fu;Sun, Hsin-Yun;Liu, Wen-Chun;Su, Yi-Ching;Hung, Chien-Ching;Chang, Shan-Chwen
core   +3 more sources

ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients

Frontiers in Genetics, 2012
The ABCB1 gene encodes P-glycoprotein, an ATP-dependent drug efflux pump, which is responsible for drug transport across extra- and intra-cellular membranes.
Marelize eSwart, Yuan eRen, Peter eSmith, Collet eDandara   +3 more
doaj   +1 more source

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers

Clinical and Translational Science, 2019
We investigated the effect of efavirenz on the activities of cytochrome P450 (CYP)1A2, CYP2A6, xanthine oxidase (XO), and N‐acetyltransferase 2 (NAT2), using caffeine as a probe.
Ingrid F. Metzger, Nimita Dave, Yvonne Kreutz, Jessica B.L. Lu, Raymond E. Galinsky, Zeruesenay Desta   +5 more
doaj   +1 more source

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. [PDF]

PLoS ONE, 2011
WHO recommends starting therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and two nucleoside reverse transcriptase inhibitors (NRTIs), i.e. nevirapine or efavirenz, with lamivudine or emtricitabine, plus zidovudine or tenofovir.
Nicole Ngo-Giang-Huong, Gonzague Jourdain, Billy Amzal, Pensiriwan Sang-a-gad, Rittha Lertkoonalak, Naree Eiamsirikit, Somboon Tansuphasawasdikul, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Sripetcharat Mekviwattanawong, Kenneth McIntosh, Marc Lallemant, Program for HIV Prevention and Treatment (PHPT) study group   +12 more
doaj   +1 more source